Vir Biotechnology
Apr 07, 2020
Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19
Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative brea...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
